137 related articles for article (PubMed ID: 29041009)
21. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
22. A functional variant of Fcgamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies.
Matsumoto I; Zhang H; Muraki Y; Hayashi T; Yasukochi T; Kori Y; Goto D; Ito S; Tsutsumi A; Sumida T
Arthritis Res Ther; 2005; 7(6):R1183-8. PubMed ID: 16277670
[TBL] [Abstract][Full Text] [Related]
23. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.
Lin TS; Flinn IW; Modali R; Lehman TA; Webb J; Waymer S; Moran ME; Lucas MS; Farag SS; Byrd JC
Blood; 2005 Jan; 105(1):289-91. PubMed ID: 15217834
[TBL] [Abstract][Full Text] [Related]
24. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Erbe AK; Wang W; Goldberg J; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Mier JW; Panka DJ; McDermott DF; Sondel PM
Clin Cancer Res; 2017 May; 23(9):2159-2168. PubMed ID: 27742794
[No Abstract] [Full Text] [Related]
25. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
Robinson JI; Md Yusof MY; Davies V; Wild D; Morgan M; Taylor JC; El-Sherbiny Y; Morris DL; Liu L; Rawstron AC; Buch MH; Plant D; Cordell HJ; Isaacs JD; Bruce IN; Emery P; Barton A; Vyse TJ; Barrett JH; Vital EM; Morgan AW; ;
EBioMedicine; 2022 Dec; 86():104343. PubMed ID: 36371989
[TBL] [Abstract][Full Text] [Related]
26. Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.
Lee YH; Song GG
Int J Rheum Dis; 2023 Jul; 26(7):1295-1304. PubMed ID: 37114884
[TBL] [Abstract][Full Text] [Related]
27. FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.
Lejeune J; Piègu B; Gouilleux-Gruart V; Ohresser M; Watier H; Thibault G
MAbs; 2012; 4(6):784-7. PubMed ID: 23032993
[TBL] [Abstract][Full Text] [Related]
28. FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome.
Rossi GM; Bonatti F; Adorni A; Alberici F; Bodria M; Bonanni A; Ghiggeri GM; Martorana D; Vaglio A
Immunol Lett; 2018 Jan; 193():11-13. PubMed ID: 29155175
[TBL] [Abstract][Full Text] [Related]
29. Role of farletuzumab in epithelial ovarian carcinoma.
Jelovac D; Armstrong DK
Curr Pharm Des; 2012; 18(25):3812-5. PubMed ID: 22591419
[TBL] [Abstract][Full Text] [Related]
30. The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes T; Melchardt T; Hufnagl C; Weiss L; Mittermair C; Neureiter D; Klieser E; Rinnerthaler G; Roesch S; Gaggl A; Greil R; Egle A
Pharmacogenomics J; 2018 May; 18(3):474-479. PubMed ID: 28719596
[TBL] [Abstract][Full Text] [Related]
31. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
Shepshelovich D; Townsend AR; Espin-Garcia O; Latifovic L; O'Callaghan CJ; Jonker DJ; Tu D; Chen E; Morgen E; Price TJ; Shapiro J; Siu LL; Kubo M; Dobrovic A; Ratain MJ; Xu W; Mushiroda T; Liu G
Cancer Med; 2018 Nov; 7(11):5478-5487. PubMed ID: 30318772
[TBL] [Abstract][Full Text] [Related]
32. Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.
Ajeganova S; Tesfa D; Hägglund H; Fadeel B; Vedin I; Zignego AL; Palmblad J
Arthritis Res Ther; 2017 Mar; 19(1):44. PubMed ID: 28270182
[TBL] [Abstract][Full Text] [Related]
33. Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis.
Lee YH; Song GG
Pharmacogenomics J; 2023 Nov; 23(6):210-216. PubMed ID: 37149714
[TBL] [Abstract][Full Text] [Related]
34. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
Geva R; Vecchione L; Kalogeras KT; Jensen BV; Lenz HJ; Yoshino T; Paez D; Montagut C; Souglakos J; Cappuzzo F; Cervantes A; Frattini M; Fountzilas G; Johansen JS; Høgdall EV; Zhang W; Yang D; Yamazaki K; Nishina T; Papamichael D; Vincenzi B; Macarulla T; Loupakis F; De Schutter J; Spindler KL; Pfeiffer P; Ciardiello F; Piessevaux H; Tejpar S
Gut; 2015 Jun; 64(6):921-8. PubMed ID: 25011934
[TBL] [Abstract][Full Text] [Related]
35. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis.
Morgan AW; Robinson JI; Barrett JH; Martin J; Walker A; Babbage SJ; Ollier WE; Gonzalez-Gay MA; Isaacs JD
Arthritis Res Ther; 2006; 8(4):R109. PubMed ID: 16846526
[TBL] [Abstract][Full Text] [Related]
36. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.
Ghesquières H; Larrabee BR; Haioun C; Link BK; Verney A; Slager SL; Ketterer N; Ansell SM; Delarue R; Maurer MJ; Fitoussi O; Habermann TM; Peyrade F; Dogan A; Molina TJ; Novak AJ; Tilly H; Cerhan JR; Salles G
Hematol Oncol; 2017 Dec; 35(4):447-455. PubMed ID: 27282998
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
38. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.
Roca L; Diéras V; Roché H; Lappartient E; Kerbrat P; Cany L; Chieze S; Canon JL; Spielmann M; Penault-Llorca F; Martin AL; Mesleard C; Lemonnier J; de Cremoux P
Breast Cancer Res Treat; 2013 Jun; 139(3):789-800. PubMed ID: 23780683
[TBL] [Abstract][Full Text] [Related]
39. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
Konner JA; Bell-McGuinn KM; Sabbatini P; Hensley ML; Tew WP; Pandit-Taskar N; Vander Els N; Phillips MD; Schweizer C; Weil SC; Larson SM; Old LJ
Clin Cancer Res; 2010 Nov; 16(21):5288-95. PubMed ID: 20855460
[TBL] [Abstract][Full Text] [Related]
40. [Effect of FCGR3A Polymorphisms on Antibody-dependent Cetuximab-mediated Cytotoxicity in A549 Cells].
Li JY; Zhu YY; Zhang GQ; Sun SJ; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Dec; 37(6):645-9. PubMed ID: 26725386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
